FIBRESOLVE for ILD and IPF Analysis — FDA authorized, evidence-based AI and machine learning-based algorithm assessment of ILD and IPF. Read the full release.
Find ILD, with tested AI. ScreenDx.
Advanced pulmonary care at the convergence of lung science and machine learning.
Learn about the ease-of-use of ScreenDx.
Using modern artificial intelligence combined with a quiet, backend design, ScreenDx is a pioneering, first-of-its-kind, FDA-cleared technology for automatically assessing CT scans for interstitial lung findings compatible with ILD.
Enhancing Workflow With ScreenDx
ScreenDx is a quiet, background-only technology that automatically sifts through thousands of CT scans to find cases with interstitial lung findings compatible with ILD.
Tested against COVID, cancer, COPD/emphysema, and many other disease states, ScreenDx is validated to pick out ILD among a wide range of scans, helping enhance referral workflow to patients with possible ILD including IPF. And it's truly automated -- no technologist or other expert user is needed to operate the tool. That's how ScreenDx can help with finding and driving referrals for patients with a range of critical, often undiagnosed ILDs.
ScreenDx is FDA-cleared to assess for interstitial lung findings compatible with ILD.
Request more info
Clinical Validation
Warning: The following list of scientific publications may contain information on the use of technology that is not part of FDA-authorized applications. It represents peer-reviewed research, including potential off-label descriptions.
Chen SJ, Kalra A, Muelly M, Reicher J, Callahan S, Scholand MB, Kulkarni T. Automated artificial intelligence detection of early or under-diagnosed interstitial lung disease by computed tomography in the COPDGene trial. Respir Med. 2025;250:108545. [link]
Batchu S, Callahan SJ, Scholand MB, Kalra A, Muelly M, Reicher J, Kulkarni T. Automated AI detection of interstitial lung disease by computed tomography (CT) in the COPDGene trial; subanalysis and characteristics of accurately detected cases [abstract]. Am J Respir Crit Care Med. 2025;211:A2087. [link]
Toulomes N, Gagianas G, Bradley J, et al. ScreenDx, an artificial intelligence-based algorithm for the incidental detection of pulmonary fibrosis. AJMS. 2025; pre-proof published online February 27, 2025. [link]
Bradley J, Kalra A, Muelly M, Reicher J. The impact of CT manufacturer and slice thickness on the ability of ScreenDx, an AI-based algorithm, to detect incidental pulmonary fibrosis. Poster presented at: 2024 American Thoracic Society Conference; May, 2024; San Diego, CA. [link]
Kulkarni T, Kalra A, Muelly M, Reicher J. Automated AI detection of clinical interstitial lung disease by CT in the COPDGene trial. Poster presented at: 2024 American Thoracic Society Conference; May, 2024; San Diego, CA. [link]
Toulomes N, Kalra A, Bradley JA, Gagianas G, Muelly M, Reicher J. Artificial intelligence in incidental detection of lung fibrosis by computed tomography. Oral presentation at: 2023 CHEST Conference; October, 2023; Honolulu, HI. [link]
Selvan KC, Kalra A, Reicher J, Muelly M, Adegunsoye A. Computer-Aided Pulmonary Fibrosis Detection Leveraging an Advanced Artificial Intelligence Triage and Notification Software. J Clin Med Res. 2023 Sep;15(8-9):423-429. [link]
